Boehringer Ingelheim GmbH, of Ingelheim, Germany, reported data showing that once-daily olodaterol, a long-acting beta2-agonist, as a maintenance treatment in chronic obstructive pulmonary disease provided a significant and identical increase in the lung function parameter FEV1 over a 24-hour period compared to twice-daily treatment, when delivered via the Respimat inhaler
Theravance and GSK have been collaborating since 2002 on a long-acting beta2 agonist (LABA) deal, and GSK is expected to file for approval this year for Relovair, an inhaled corticosteroid/LABA combination product, in chronic obstructive pulmonary disease. (See BioWorld Today, March 26, 2012
Bioxyne is expected to release data later this year from a 320-patient trial testing vaccine candidate HI-164OV in chronic obstructive pulmonary disease. (See BioWorld Today, April 9, 2012
and Europe in the middle of this year for chronic obstructive pulmonary disease, following the completion of the Phase III program...The merged entity, which will be renamed Bioxyne and will focus on a midstage chronic obstructive pulmonary disease candidate, is due to relist on the Australian exchange on April 4
The merged entity, which will be renamed Bioxyne and will focus on a midstage chronic obstructive pulmonary disease candidate, is due to relist on the Australian exchange on April 4
Forest Laboratories Inc., of New York, and Almirall SA, of Barcelona, Spain, said the FDA will require a three-month extension to complete its review of the new drug application for aclidinium bromide, a long-acting antimuscarinic drug, for the maintenance treatment of chronic obstructive pulmonary disease
Almirall SA, of Barcelona, Spain, said the European Respiratory Journal published full results of ATTAIN (Aclidinium To Treat Airway obstruction In COPD patieNts), a six-month pivotal study comparing the efficacy and safety of twice-daily inhaled aclidinium (200 mcg and 400 mcg) against placebo in patients with moderate to severe chronic obstructive pulmonary disease
BioWorld International | Wednesday, March 28, 2012
The deal included Orexo's OX-CLI and OX-ESI programs in asthma and obstructive pulmonary disease, which the Swedish biotech now plans to shelve, and an undisclosed Janssen program
BioWorld International | Wednesday, February 8, 2012
The deal included Orexo's OX-CLI and OX-ESI programs in asthma and obstructive pulmonary disease, which the Swedish biotech now plans to shelve, and an undisclosed Janssen program. (See BioWorld Today, June 2, 2010
LTA4H and receptors to LTB4 are known to be elevated in a number of human lung diseases, including cystic fibrosis, asthma and chronic obstructive pulmonary disease
At the close of the acquisition, Hunter shareholders will own about 89 percent of the new company, and the firm's development pipeline will include Hunter's Phase IIb-stage vaccine for chronic obstructive pulmonary disorder
BioWorld International | Wednesday, December 21, 2011
At the close of the acquisition, Hunter shareholders will own about 89 percent of the new company, and the firm's development pipeline will include Hunter's Phase IIb-stage vaccine for chronic obstructive pulmonary disorder
ProtAffin AG, of Graz, Austria, received a €2.1 million (US$2.7 million) award from the Austrian Forschungs-Forderungs-Gesellschaft (FFG) for the preclinical and clinical development of lead product PA401 in inflammatory lung diseases, including chronic obstructive pulmonary disease
In other news, Almirall and Forest Laboratories Inc., of New York, began a Phase III trial of a fixed-dose combination of aclidinium bromide and formoterol fumarate via the Genuair inhaler for chronic obstructive pulmonary disease (COPD
BioWorld International | Wednesday, November 23, 2011
Median time to progression among the breast cancer group was 2.5 months, and median overall survival was 13.7 months...Otsuka will receive up to $1 .4 billion in total for the up-front payment and development and regulatory milestones...Sales milestones will pay up to an additional $1.8 billion
BioWorld International | Wednesday, November 16, 2011
Amakem NV, of Diepenbeek, Belgium, reported data showing that AMA0247, a selective Rho kinase inhibitor, was effective in inhibiting the inflammatory reaction in the lungs, as measured by neutrophil infiltration, but had no effect on blood pressure or heart rate in a smoking mouse model for chronic obstructive pulmonary disease
BioWorld International | Wednesday, November 9, 2011
Amakem NV, of Diepenbeek, Belgium, reported data showing that AMA0247, a selective Rho kinase inhibitor, was effective in inhibiting the inflammatory reaction in the lungs, as measured by neutrophil infiltration, but had no effect on blood pressure or heart rate in a smoking mouse model for chronic obstructive pulmonary disease
Boehringer Ingelheim GmbH, of Ingelheim, Germany, reported data showing that once-daily olodaterol, a long-acting beta2-agonist, as a maintenance treatment in chronic obstructive pulmonary disease provided a significant and identical increase in the lung function parameter FEV1 over a 24-hour period compared to twice-daily treatment, when delivered via the Respimat inhaler